NCT05869955Active, not recruitingPhase 1

A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, or Rheumatoid Arthritis (Breakfree-1)

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company82 sites in 5 countries270 target enrollmentStarted: September 13, 2023Last updated: August 3, 2026

Conditions

Interventions

Drugs

Trial Snapshot

Phase: Phase 1
Status: Active, not recruiting
Sponsor
Enrollment: 270
Locations: 82
Primary Endpoint: Number of participants with treatment-emergent adverse events (AEs) in each indication.

Study Overview Study Design Eligibility Criteria Arms & Interventions Outcomes Investigators Sites Records & Identifiers Similar Trials Related News

Study Overview

Brief Summary

The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).

Study Design

Study Type: Interventional
Allocation: Na
Intervention Model: Single Group
Primary Purpose: Treatment
Masking: None

Eligibility Criteria

Ages: 18 Years to — (Adult, Older Adult)
Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

•- Diagnosis of Systemic Lupus Erythematosus (SLE) defined as follows:.
•i) Fulfilling the 2019 European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) classification criteria of SLE.
•ii) Presence of anti-dsDNA, anti-histone, anti-chromatin, anti-Ro (anti-SS-A), anti-La (anti-SS-B), or anti-Sm antibodies at screening.
•- SLE disease activity:.
•i) Active disease at screening, with recent ≥ 1 major organ system with a BILAG A score (excluding musculoskeletal, mucocutaneous, and/or constitutional organ system).
•ii) Inadequate response to glucocorticoids and to at least 2 of the following treatments, used for at least 3 months each: cyclophosphamide, mycophenolic acid or its derivatives, belimumab, azathioprine, anifrolumab, methotrexate, rituximab, obinutuzumab, cyclosporin, tacrolimus or voclosporin.
•Diagnosis of Idiopathic Inflammatory Myopathy (IIM) defined as follows:.
•i) Fulfilling the 2017 EULAR/ACR classification criteria for probable or definite IIM.
•ii) Participant diagnosed with the following IIM subgroups: dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and polymyositis (PM).
•iii) Presence of at least 1 myositis specific antibody (MSA), associated antibody (MAA), or ANA at screening or prior to screening.
•IIM disease activity:.
•i) Severe/moderate muscle AND/OR skin involvement.
•ii) Proof of activity as documented by:.
•A. An active myositis-associated rash OR.
•B. A recent muscle biopsy OR.
•C. An elevated CK > 3 times the upper limit of normal OR.
•D. Participants diagnosed IIM AND progressive Interstitial Lung Disease (ILD) on high-resolution computed tomography (HRCT)
•iii) Inadequate response to glucocorticoids and at least 2 of the following treatments used for at least 3 months: azathioprine, methotrexate, cyclosporin A, tacrolimus, MMF, cyclophosphamide, IVIG, JAK inhibitors, and rituximab.
•Diagnosis of Systemic Sclerosis (SSc) defined as follows:.
•i) Fulfilling 2013 EULAR/ACR classification criteria for SSc.
•ii) Antinuclear Antibody (ANA) positive at screening or prior to screening.
•- SSc disease activity:.
•i) Participants diagnosed with diffuse cutaneous SSc OR diffuse or limited cutaneous SSc AND progressive ILD, AND.
•ii) Inadequate response to at least 1 of the following treatments used for at least 3 months: mycophenolate, cyclophosphamide, rituximab, nintedanib, azathioprine, tocilizumab, or intravenous immunoglobulins (IVIG).
•- Rheumatoid Arthritis (RA) disease activity:.
•i) Minimum of 3 SJC and 3 TJC on a 66/68 joint count (SJC/TJC).
•ii) OR participants diagnosed with progressive ILD (interstitial lung disease).
•iii) AND Inadequate disease response or intolerance to at least one conventional synthetic disease-modifying antirheumatic drug (DMARD) and as well as ≥ 2 DMARDs with different mechanisms of action from the categories biologic disease-modifying antirheumatic drug (bDMARDs) or targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) for a minimum of 3 months.
•A. Participants qualifying on progressive ILD may have exhausted the therapies above OR have demonstrated inadequate disease response or intolerance to at least one of the following treatments used for at least 3 months: mycophenolate, tocilizumab, cyclophosphamide, rituximab, azathioprine, nintedinib, pirfenidone.

Exclusion Criteria

•- Diagnosis of drug-induced SLE rather than idiopathic SLE.
•- Other systemic autoimmune diseases (eg, multiple sclerosis, psoriasis, inflammatory bowel disease, etc) are excluded. Participants with type I autoimmune diabetes mellitus, thyroid autoimmune disease, Celiac disease, or secondary Sjögren's syndrome are not excluded.
•SLE overlap syndromes including, but not limited to, rheumatoid arthritis, scleroderma, and mixed connective tissue disease, are excluded.
•Present or recent clinically significant CNS pathology, within 12 months.
•IIM disease activity:.
•i) Other forms of IIM: Inclusion Body Myositis, Amyopathic DM, any form of juvenile myositis.
•ii) Myositis other than IIM, eg, drug-induced myositis and PM associated with HIV.
•iii) Participants with severe muscle damage (Physician VAS for muscle damage in Myositis Damage Index > 7 cm on a 10 cm scale), permanent weakness due to a non-IIM cause (eg, stroke), or myositis with cardiac involvement.
•- SSc disease activity:.
•i) SSc related PAH requiring active treatment.
•ii) Rapidly progressive SSc related lower GI (small and large intestines) involvement (requiring parenteral nutrition); active gastric antral vascular ectasia.
•iii) Prior scleroderma renal crisis.
•- RA disease activity:.
•i) Prior history of or current inflammatory joint disease other than RA.
•ii) Joint damage and/or deformity that may confound the investigator's ability to accurately assess disease activity.
•- Other protocol-defined Inclusion/Exclusion criteria apply.

Arms & Interventions

Administration of CC-97540

Experimental

Intervention: CC-97540 (Drug)

Administration of CC-97540

Experimental

Intervention: Tocilizumab (Drug)

Administration of CC-97540

Experimental

Intervention: Fludarabine (Drug)

Administration of CC-97540

Experimental

Intervention: Cyclophosphamide (Drug)